Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Contraception
Interventions: AG200-15 (cycles 1-13), Lessina crossover to AG200-15; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 17 Years to 40 Years · Female only
Enrollment: 1,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 80
States / cities: Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more

Conditions: Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions: Standard care, Metformin, Placebo; Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 20 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Absence Epilepsy, Ketogenic Dieting, Epilepsy, Absence
Interventions: Modified Atkins Diet, Absence epilepsy medications; Other · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
Interventions: locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2; Biological · Drug
Lead sponsor: David Bartlett, MD; Other
Eligibility: 18 Years to 79 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Substance Abuse Disorder
Interventions: Low intensity care, Voucher reinforcement; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
Interventions: Placebo, Doxazosin; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteo Arthritis Knee
Interventions: Ropivacaine; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Hepatocellular Carcinoma Non-resectable
Interventions: Fluorine-18 fluorocholine; Combination Product
Lead sponsor: Queen's Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Commack, New York • Harrison, New York • New York, New York + 5 more

Conditions: Bipolar Disorder
Interventions: Metformin, healthy lifestyle intervention (LIFE); Drug · Behavioral
Lead sponsor: Melissa Delbello; Other
Eligibility: 8 Years to 19 Years
Enrollment: 1,565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 29
States / cities: Covington, Kentucky • Neptune City, New Jersey • Amityville, New York + 13 more

Conditions: Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure
Interventions: Ensure Plus®, Pre-clinical validation contrast enhanced MRI, Clinical validation MRI, Pre-clinical validation contrast enhanced MRI + fasting; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Fibromyalgia
Interventions: TNX-102 SL, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 33 more

Conditions: Facial Injuries, Traumatic Wounds and Injuries, Craniofacial Injuries, Craniofacial Defects, Facial Transplantation, Facial Deformity
Interventions: Bone marrow cell-based therapy & 1-drug immunosuppression.; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2041
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: TAK-788, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions: AAV2-hAADC; Drug
Lead sponsor: Russell Lonser; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 76
States / cities: Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more

Conditions: Autism Spectrum Disorder
Interventions: Minocycline; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions: Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 27
States / cities: Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more

Conditions: Dravet Syndrome (DS)
Interventions: Soticlestat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more

Conditions: Parenteral Nutrition-Associated Liver Disease
Interventions: Intravenous fat emulsion, Restriction of intravenous fat emulsion to 1 gm/kg/d; Other
Lead sponsor: Yale University; Other
Eligibility: 12 Hours to 48 Hours
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostate Cancer
Interventions: Rapamycin 3mg, Rapamycin 6mg, Radical prostatectomy; Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Ann Arbor, Michigan • Durham, North Carolina

Conditions: Alcohol Use Disorder
Interventions: ANS-6637 Low Dose, ANS-6637 High Dose, Matched Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Palmar Hyperhidrosis
Interventions: Dexmecamylamine HCl, Placebo; Drug · Other
Lead sponsor: Atacama Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: San Diego, California • St Louis, Missouri • Norfolk, Virginia

Search by objective public record fields.

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

Metformin to Augment Low Milk Supply (MALMS) Study

Ketogenic Diet for New-Onset Absence Epilepsy

Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease

Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance

The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine

High Versus Low Adductor Canal Block

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

Human Craniomaxillofacial Allotransplantation

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

AAV2-hAADC for Parkinson's Disease (PDCS-01)

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

Measuring Brain Inflammation in Autism

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates

Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer

Development of a Selective ALDH2 Inhibitor to Treat AUD

Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis